Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia (Q86433063)

From Wikidata

Jump to navigation Jump to search

scientific article published on 19 March 2013

Language	Label	Description	Also known as
English	Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia	scientific article published on 19 March 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23512246%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23512246%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

T-cell prolymphocytic leukemia

1 reference

based on heuristic

inferred from title

Georg Hopfinger

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23512246%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Barbara Eichhorst

14

object named as

Barbara Eichhorst

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23512246%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Stephan Stilgenbauer

11

object named as

Stephan Stilgenbauer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23512246%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

author name string

Raymonde Busch

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23512246%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Natali Pflug

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23512246%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Nicole Weit

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23512246%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Anne Westermann

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23512246%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Anna-Maria Fink

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23512246%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Paula Cramer

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23512246%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Nina Reinart

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23512246%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Dirk Winkler

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23512246%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Günter Fingerle-Rowson

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23512246%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Hartmut Döhner

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23512246%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Gabriele Kandler

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23512246%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Michael Hallek

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23512246%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Marco Herling

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23512246%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

publication date

19 March 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23512246%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

number of pages

10

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23512246%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

119

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23512246%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23512246%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

2258-2267

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23512246%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27972

7 January 2021

based on heuristic

inferred from DOI database lookup

A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27972

7 January 2021

based on heuristic

inferred from DOI database lookup

High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27972

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of T-cell prolymphocytic leukemia with human CD52 antibody

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27972

7 January 2021

based on heuristic

inferred from DOI database lookup

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27972

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27972

7 January 2021

based on heuristic

inferred from DOI database lookup

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27972

7 January 2021

based on heuristic

inferred from DOI database lookup

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27972

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27972

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27972

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27972

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular cytogenetic detection of chromosomal breakpoints in T-cell receptor gene loci

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27972

7 January 2021

based on heuristic

inferred from DOI database lookup

T-cell prolymphocytic leukemia: a single-institution experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27972

7 January 2021

based on heuristic

inferred from DOI database lookup

Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27972

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27972

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27972

7 January 2021

based on heuristic

inferred from DOI database lookup

Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27972

7 January 2021

based on heuristic

inferred from DOI database lookup

Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27972

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27972

7 January 2021

based on heuristic

inferred from DOI database lookup

Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27972

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27972

7 January 2021

based on heuristic

inferred from DOI database lookup

No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27972

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27972

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27972

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.27972

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23512246%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23512246%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q86433063&oldid=1933886308"